The project is funded by the European Community’s
Seventh Framework Programme under grant agreement
No. HEALTH-F2-2010-241909 (Project EU-GEI).
  • Two new EU-GEI tools available  -  FINAL EU-GEI NEWSLETTER available

About the project

The aim of EU-GEI is to identify, over a 5-year period, the interactive genetic, clinical and environmental determinants, involved in the development, severity and outcome of schizophrenia. The partners in EU-GEI represent the nationally funded schizophrenia / mental health networks of the UK, Netherlands, France, Spain, Turkey and Germany, as well as other research institutes and a number of SME’s in Austria, Belgium, Ireland, Italy, Switzerland, and outside the EU in Hong Kong/China and Australia.

The project will commence on May 1, 2010 and run until May 1, 2015.

In order to identify the genetic, clinical and environmental determinants and their interactions, EU-GEI will employ family-based, multidisciplinary study paradigms, which allow for efficient assessment of gene-environment interactions.  Translation of results to clinical practice will be facilitated by additional experimental research and risk assessment bioinformatics research. This will enable (i) the identification of modifiable biological and cognitive pathways and mechanisms and (ii) the construction of Risk Assessment Charts and Momentary Assessment Technology tools which can be used for the early prediction of (i) transition to psychotic disorder in at-risk help-seeking individuals, (ii) diagnosis and (iii) outcome monitoring.


EU-GEI has assembled a diverse multidisciplinary team of top schizophrenia researchers who have the range of skills required to deliver a program of research that meets all the call’s requirements and have access to / will collect a number of unique samples, described below.

EU-GEI will additionally include a user-led PhD project, and aims to impact on mental health and societal issues as called for in the European Parliament Resolution on Mental Health in Europe (INI/2006/2058 – see B3, impact).


The project is coordinated by Maastricht University (MUMC). Project Coordinator is Professor Jim van Os, Director of clinical research in MHeNS, the research School Mental Health and Neuroscience at MUMC and head of the research line of Psychiatric Ecogenetics, or gene-environment interactions (GxE).